Partnership


Partner:

yhan-logo-web

Asset Type:

Immuno-Oncology

Partner Background:

Yuhan Corporation is one of the largest Korean pharmaceutical companies, founded over 80 years ago

Partnership Details:

Joint Venture named ImmuneOncia Therapeutics, LLC

Focused on developing and commercializing a number of immune checkpoint antibodies for hematological malignancies and solid tumors


Partner:

Asset Type:

Immuno-Oncology

Partner Background:

Lee’s Pharm is a public biopharma company with over 20 years of operation in China and currently markets 14 products in the PRC

Partnership Details:

Sorrento has licensed exclusive rights to Lee’s Pharm to develop and commercialize the fully human anti-PD-L1 mAb STI-A1014 for the greater Chinese market


Partner:

celularity-logo-web

Asset Type:

Cellular Therapy

Partner Background:

Celularity is a spin-off from Celgene Corporation focusing on placenta-derived and cord-blood derived cells therapies

Partnership Details:

License of product rights to Celularity in exchange for equity


Partner:

mabpharm-logo01

Asset Type:

Immuno-Oncology

Partner Background:

MABPHARM is a Biopharma focusing on the R&D and Production of new drugs and Biosimilars for cancers and autoimmune diseases

Partnership Details:

Collaboration on development and commercialization of ACE-MAB™ to potentially treat COVID-19


At Sorrento, we seek strong partnerships and collaborations as a critical driver of our strategy to push the boundaries of science and deliver life-changing therapies to patients so they can live healthier and happier lives.